^
Association details:
| Biomarker: | ER negative + HER-2 positive + PGR positive + PIK3CA mutation |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Irene (pyrotinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Pyrotinib in the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer
Published date:
06/19/2020
Excerpt:
She was presented with estrogen receptor-negative, progesterone receptor-positive (1+), and HER2-positive...phosphoinositol-3 kinase (PIK3CA) mutation was discovered…The patient received 6 cycles of pyrotinib in combination with capecitabine regularly. Progression free survival was more than 6 months, and the patient's efficacy evaluation was partial remission.
DOI:
10.1097/MD.0000000000020809
